Premium
Severe cytokine release syndrome in a patient receiving PD‐1‐directed therapy
Author(s) -
Rotz Seth J.,
Leino Daniel,
Szabo Sara,
Mangino Jennifer L.,
Turpin Brian K.,
Pressey Joseph G.
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26642
Subject(s) - medicine , tocilizumab , cytokine release syndrome , blockade , immunotherapy , cytokine , coagulopathy , immune system , immune checkpoint , encephalopathy , cytokine storm , immunology , receptor , covid-19 , chimeric antigen receptor , disease , infectious disease (medical specialty)
Cytokine release syndrome (CRS) is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T‐cell engaging immunotherapy. Checkpoint blockade using anti‐programmed cell death 1 (anti‐PD‐1) inhibitors is an approach to antitumor immune system stimulation. A 29‐year‐old female with alveolar soft part sarcoma developed severe CRS after treatment with anti‐PD‐1 therapy. CRS was characterized by high fevers, encephalopathy, hypotension, hypoxia, hepatic dysfunction, and evidence of coagulopathy, and resolved after infusion of the interleukin‐6 inhibitor tocilizumab and corticosteroids.